FDA Advisory Committee Review of Supplemental Indications and Reasons for Non-Approval, 2008-2022
Journal of Law, Medicine & Ethics · 2025 · 53 (1) · 137-144
DOI: 10.1017/jme.2025.53 ↗Kurz gefasst
Fachartikel in der Zeitschrift Journal of Law, Medicine & Ethics, online erschienen am 08.04.2025. Verfasst von Audrey D Zhang und 4 weiteren Autor:innen. Beteiligte Einrichtung: Division of General Medicine, Beth Israel Deaconess Medical Center, Boston, Massachusetts, United States. Die Arbeit wurde bisher 2-mal zitiert (Crossref) und nennt 18 Literaturangaben. Gefördert von: Arnold Ventures.
Abstract (Originalsprache)
This study characterizes 2008-2022 FDA advisory committee discussions of new supplemental indication applications that were not approved by FDA. Discussion themes included contextual concerns unique to already-approved drugs, including insights from prior experience and concerns about off-label use, and efficacy and safety concerns also observed for new drugs. These findings highlight advisory committees’ role in transparency of regulatory decision-making, specifically for drugs already authorized for use.
Schlagwörter
Stichwörter der Autor:innen
Autor:innen und Institutionen
- Division of General Medicine, Beth Israel Deaconess Medical Center, Boston, Massachusetts, United States.
- Harvard Law School, Cambridge, Massachusetts, United States.
- General Internal Medicine, Yale School of Medicine, New Haven, Connecticut, United States.
- Department of Health Policy and Management, Yale University, New Haven, Connecticut, United States.
ORCID-Profile: Audrey D Zhang, Reshma Ramachandran
Förderung
- Arnold Ventures
Zitieren
APA
Zhang, A. D., Chaudhry, N., Ramachandran, R., Ross, J. S., & Schwartz, J. L. (2025). FDA Advisory Committee Review of Supplemental Indications and Reasons for Non-Approval, 2008-2022. Journal of Law, Medicine & Ethics, 53(1), 137-144. https://doi.org/10.1017/jme.2025.53
Vancouver
Zhang AD, Chaudhry N, Ramachandran R, Ross JS, Schwartz JL. FDA Advisory Committee Review of Supplemental Indications and Reasons for Non-Approval, 2008-2022. Journal of Law, Medicine & Ethics. 2025;53(1):137-144. doi:10.1017/jme.2025.53
BibTeX
@article{Zhang2025,
author = {Zhang, Audrey D and Chaudhry, Nikhil and Ramachandran, Reshma and Ross, Joseph S and Schwartz, Jason L},
title = {FDA Advisory Committee Review of Supplemental Indications and Reasons for Non-Approval, 2008-2022},
journal = {Journal of Law, Medicine & Ethics},
year = {2025},
volume = {53},
number = {1},
pages = {137--144},
doi = {10.1017/jme.2025.53}
}
EUVIMED